D-1315-2020 Class III Terminated

Recalled by Aurobindo Pharma USA Inc. — East Windsor, NJ

FDA drug recall D-1315-2020 was initiated by Aurobindo Pharma USA Inc. on May 26, 2020 and is designated Class III. Reason for recall: Failed Impurities/ Degradation Specifications The recall status is terminated (terminated Jan 10, 2023). Affected quantity: 7547 bottles.

Recall details

Product Type
Drugs
Report Date
Jun 24, 2020
Initiation Date
May 26, 2020
Termination Date
Jan 10, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
7547 bottles

Product description

Olanzapine Tablets, USP 7.5 mg, 30-count bottle, Rx only, Manufactured for: Prasco Laboratories Mason, OH 45040 USA, Manufactured by: Aurolife Pharma LLC Dayton, NJ 08810, NDC 66993-682-30

Reason for recall

Failed Impurities/ Degradation Specifications

Distribution pattern

U.S.A. Nationwide

Code information

Lot #: 563180012A1, Exp 8/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1315-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1315-2020. Report a data issue: hello@regdatalab.com.